连续皮下氯胺酮输注可能诱导他克莫司和西罗莫司清除:一例病例报告
一例55岁男性心脏移植受者在下肢血栓切除术后接受连续皮下氯胺酮(5.2-10.4 mg/h)镇痛,他克莫司和西罗莫司浓度在剂量分别增加1.8倍和5倍后仍低于治疗范围。群体药代动力学建模显示氯胺酮给药期间清除率约增加2倍,峰值在开始后1周,停药后3周内浓度逐渐回升,提示可能为酶诱导作用。
要点
- 氯胺酮连续皮下输注期间他克莫司和西罗莫司清除率约增加2倍。
- 尽管剂量增加1.8倍和5倍,两者浓度仍低于治疗范围。
- 停药后浓度约3周逐渐恢复,提示酶诱导与恢复过程。
核心结论
- 本病例初步提示氯胺酮与CYP3A4代谢的免疫抑制剂之间可能存在相互作用。
- 药物相互作用概率量表评估为可能相互作用(评分+5)。
研究设计与样本
- 单例病例报告:55岁男性心脏移植受者,下肢血栓切除术后接受连续皮下氯胺酮(5.2-10.4 mg/h)镇痛。
- 采用群体药代动力学建模与贝叶斯估计,纳入六个时期(氯胺酮给药前、给药期间及停药后4周每周)的场合间变异。
主要发现
- 氯胺酮开始后,他克莫司和西罗莫司浓度虽经剂量分别增加1.8倍和5倍仍低于治疗范围。
- 药代动力学建模显示氯胺酮给药期间清除率约增加2倍,峰值在开始后1周。
- 停药后他克莫司和西罗莫司浓度在3周内逐渐升高,与酶诱导和恢复一致。
- 短暂合用氟氯西林可能对观察到的变化有贡献。
临床怎么用
- 使用氯胺酮与窄治疗范围药物(如他克莫司、西罗莫司)时,应考虑加强治疗药物监测。
- 监测应持续至氯胺酮停药后约3周。
局限性
- 单例病例报告,不能确立因果关系。
- 短暂合用氟氯西林可能混淆观察结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Drug interactions involving immunosuppressants can compromise transplant outcomes. Although repeated ketamine administration induces hepatic enzymes in experimental models, clinical reports of induced clearance of cytochrome P450 (CYP) substrates are lacking. Continuous subcutaneous ketamine infusions are increasingly used for acute pain management. We present a case of difficult-to-maintain tacrolimus and sirolimus concentrations in the context of subcutaneous ketamine infusion for acute pain management. METHODS: A 55-year-old male heart transplant recipient received continuous subcutaneous ketamine (5.2-10.4 mg/h) for pain management following lower limb thrombectomy. Tacrolimus and sirolimus concentrations were monitored throughout hospitalization and rehabilitation. Population pharmacokinetic modeling with Bayesian estimation characterized temporal clearance changes, incorporating inter-occasion variability across six periods (pre-, during-, and weekly post-ketamine administration for 4 weeks). RESULTS: Following ketamine initiation, tacrolimus and sirolimus concentrations remained subtherapeutic despite dose escalations of 1.8-fold and 5-fold, respectively. Pharmacokinetic modeling revealed approximately 2-fold clearance increases during ketamine administration, peaking 1 week after initiation. Following ketamine discontinuation, tacrolimus and sirolimus concentrations progressively increased over 3 weeks, consistent with enzyme induction and recovery. Drug Interaction Probability Scale assessment indicated probable interaction (score + 5). Brief concomitant flucloxacillin use may have contributed to the observed changes. CONCLUSIONS: This case provides preliminary evidence of potential interaction between ketamine and CYP3A4-metabolized immunosuppressants. Clinicians should consider increased therapeutic drug monitoring when using ketamine with narrow therapeutic range medications, continuing approximately 3 weeks post-discontinuation.
引用
- Stojanova J, Murnion B, Burrows F, et al. Continuous Subcutaneous Ketamine Infusion May Induce Tacrolimus and Sirolimus Clearance: A Case Report. Pharmacotherapy. 2026. PMID: 42115000. doi:10.1002/phar.70150
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。